• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone
【24h】

Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone

机译：AbiraTerone乙酸酯治疗转移性阉割的前列腺癌与泼尼松组合

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Prostate cancer is one of the most common cancers in the United States, with an estimated incidence of 164,690 cases, accounting for 9.5% of all new cancer diagnoses. The mainstay of therapy for metastatic prostate cancer involves suppressing testosterone production through androgen deprivation therapy. However, nearly all patients on androgen deprivation therapy will develop resistance to hormone therapy. An improved understanding of the biology of castration resistance has allowed for the development of novel inhibitors of the androgen axis. Agents such as abiraterone acetate, which provides additional androgen suppression by inhibiting cytochrome P450 17A (CYP17A), have improved survival outcomes of patients with advanced prostate cancer. The longest experience with abiraterone acetate is in the metastatic castration-resistant setting. However, more recent trials have demonstrated that abiraterone acetate is an option for treatment earlier in the prostate cancer paradigm. This review will cover the current use of abiraterone acetate in combination with prednisone for the treatment of castration-resistant prostate cancer.
机译：前列腺癌是美国最常见的癌症之一，估计发病率为164,690例，占所有新癌症诊断的9.5％。转移前列腺癌的疗法的主要疗法涉及通过雄激素剥夺疗法抑制睾酮产生。然而，几乎所有关于雄激素剥夺治疗的患者都会产生对激素治疗的抵抗力。改进了对阉割抗性生物学的理解，允许开发雄激素轴的新抑制剂。通过抑制细胞色素P450 17A（CYP17A）提供诸如Abiraatorone乙酸酯的试剂，其具有提高先进前列腺癌患者的存活结果。醋酸盐的最长经验处于转移性阉割抵抗设定。然而，最近的试验表明，AbiraTerone醋酸盐是前列腺癌范式之前的治疗选择。本综述将涵盖当前使用AbiraTerone醋酸盐与泼尼松组合用于治疗抗阉割前列腺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号